Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 2
Submit an article Journal homepage
1,172
Views
78
CrossRef citations to date
0
Altmetric
Reviews

Treatment of elderly patients with chronic lymphocytic leukemia

Barbara Eichhorst Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, GermanyCorrespondence[email protected]
,
Valentin Goede Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany
&
Michael Hallek Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany
Pages 171-178 | Received 13 Oct 2008, Accepted 13 Dec 2008, Published online: 01 Jul 2009

Citations (78)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Laura S. Samples & Solomon A. Graf. (2018) On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 19:15, pages 1675-1684.
Read now
Sonia Cerquozzi & Carolyn Owen. (2015) Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 13-22.
Read now
Zahra Mozaheb. (2014) Treating the elderly patient with chronic lymphocytic leukemia: current and emerging options. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 9-14.
Read now
Loretta J Nastoupil, Rajni Sinha & Christopher R Flowers. (2013) The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Review of Anticancer Therapy 13:9, pages 1089-1108.
Read now
Stefano Molica, Maura Brugiatelli, Fortunato Morabito, Felicetto Ferrara, Emilio Iannitto, Nicola Di Renzo, Silvana Capalbo, Pellegrino Musto & Francesco Di Raimondo. (2013) Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need. Expert Review of Hematology 6:4, pages 441-449.
Read now
Ilaria Del Giudice, Francesca Romana Mauro & Robin Foà. (2011) Chronic lymphocytic leukemia in less fit patients: “slow-go”. Leukemia & Lymphoma 52:12, pages 2207-2216.
Read now
Clive S. Zent & Neil E. Kay. (2011) Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leukemia & Lymphoma 52:8, pages 1425-1434.
Read now

Articles from other publishers (71)

Sorang Kang & Inhye E. Ahn. (2023) Prognostic Markers in the Era of Targeted Therapies. Acta Haematologica, pages 1-14.
Crossref
Anthony R. Mato, Lisa M. Hess, Yongmei Chen, Paolo B. Abada, Heiko Konig, John M. Pagel & Richard A. Walgren. (2022) Outcomes for Patients With Chronic Lymphocytic Leukemia (CLL) Previously Treated With Both a Covalent BTK and BCL2 Inhibitor in the United States: A Real-World Database Study. Clinical Lymphoma Myeloma and Leukemia.
Crossref
John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A. Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F. Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni & Wojciech Jurczak. (2021) Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology 39:31, pages 3441-3452.
Crossref
Othman Al‐Sawaf, Brittany Gentile, Jacob Devine, Can Zhang, Kavita Sail, Maneesh Tandon, Anna‐Maria Fink, Nadine Kutsch, Clemens‐Martin Wendtner, Barbara Eichhorst, Michael Hallek & Kirsten Fischer. (2021) Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial . American Journal of Hematology 96:9, pages 1112-1119.
Crossref
Delphine TardivonMateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch & Freddy Radtke. (2021) Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia. Blood 137:22, pages 3079-3092.
Crossref
Daniel Eek, Matthew Blowfield, Calvin Krogh, Helena Chung & Toby A. Eyre. (2020) Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience. The Patient - Patient-Centered Outcomes Research 14:1, pages 75-87.
Crossref
Vilhjálmur Steingrímsson, Gauti K. Gíslason, Thor Aspelund, Ingemar Turesson, Magnus Björkholm, Ola Landgren & Sigurdur Y. Kristinsson. (2020) A population‐based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival. European Journal of Haematology 105:5, pages 547-554.
Crossref
Lin Yang, Sara E.F. Kost, Sara Beiggi, Yunli Zhang, Robert Schmidt, Zoann Nugent, Aaron Marshall, Versha Banerji, Spencer B. Gibson & James B. Johnston. (2019) Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia. Leukemia Research 86, pages 106220.
Crossref
Yair Herishanu, Tamar Tadmor, Andrei Braester, Osnat Bairey, Ariel Aviv, Naomi Rahimi‐Levene, Riva Fineman, Itai Levi, Mona Yuklea, Rosa Ruchlemer, Lev Shvidel & Aaron Polliack. (2019) Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. Hematological Oncology 37:2, pages 185-192.
Crossref
Faith A.A. Kwa, Merrole F. Cole-Sinclair & Miroslav K. Kapuscinski. (2019) Combination Treatment of p53-Null HL-60 cells with Histone Deacetylase Inhibitors and Chlorambucil Augments Apoptosis and Increases BCL6 and p21 Gene Expression. Current Molecular Pharmacology 12:1, pages 72-81.
Crossref
Barbara L. Andersen, Neha Godiwala Goyal, David M. Weiss, Travis D. Westbrook, Kami J. Maddocks, John C. Byrd & Amy J. Johnson. (2018) Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia. Cancer 124:15, pages 3240-3248.
Crossref
Jennifer A. Woyach. (2018) What is the optimal management of older CLL patients?. Best Practice & Research Clinical Haematology 31:1, pages 83-89.
Crossref
Godelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, Stéphane Lepretre, Anne Quinquenel, Jehan Dupuis, Richard Lemal, Thérèse Aurran, Cécile Tomowiak, Florence Cymbalista, Marie Sarah Dilhuydy, Annie Brion, Pierre Morel, Bruno Cazin, Véronique Leblond, Guillaume Cartron, Daniel Ré, Marie Christine Béné, Anne Sophie Michallet & Pierre Feugier. (2017) First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. Hematological Oncology 35:4, pages 671-678.
Crossref
Othman Al-Sawaf, Paula Cramer, Valentin Goede, Michael Hallek & Natali Pflug. (2017) Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Therapeutic Advances in Hematology 8:6, pages 197-205.
Crossref
José A. García-Marco, Julio Delgado, José A. Hernández-Rivas, Ángel Ramírez Payer, Javier Loscertales Pueyo, Isidro Jarque, Pau Abrisqueta, Pilar Giraldo, Rafael Martínez, Lucrecia Yáñez, Mª José Terol, Marcos González & Francesc Bosch. (2017) Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica. Medicina Clínica 148:8, pages 381.e1-381.e9.
Crossref
José A. García-Marco, Julio Delgado, José A. Hernández-Rivas, Ángel Ramírez Payer, Javier Loscertales Pueyo, Isidro Jarque, Pau Abrisqueta, Pilar Giraldo, Rafael Martínez, Lucrecia Yáñez, M. José Terol, Marcos González & Francesc Bosch. (2017) Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. Medicina Clínica (English Edition) 148:8, pages 381.e1-381.e8.
Crossref
O. Vyhovska, Ya. Vyhovska, O. Shalay, L. Lukavetskyy, V. Voytsitskyy, L. Shevchenko, V. Barilka & Z. Maslyak. (2017) Chronic Lymphocytic Leukemia in Elderly Patients: Own Experience. Lviv clinical bulletin 1:17, pages 26-31.
Crossref
Jeffrey A Jones, Tadeusz Robak, Jennifer R Brown, Farrukh T Awan, Xavier Badoux, Steven Coutre, Javier Loscertales, Kerry Taylor, Elisabeth Vandenberghe, Malgorzata Wach, Nina Wagner-Johnston, Loic Ysebaert, Lyndah Dreiling, Ronald Dubowy, Guan Xing, Ian W Flinn & Carolyn Owen. (2017) Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. The Lancet Haematology 4:3, pages e114-e126.
Crossref
Erin M. Pettijohn & Shuo Ma. (2017) Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). Current Hematologic Malignancy Reports 12:1, pages 20-28.
Crossref
Eleshia J. Morrison, Joseph M. Flynn, Jeffrey Jones, John C. Byrd & Barbara L. Andersen. (2016) Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. Annals of Hematology 95:12, pages 1989-1997.
Crossref
Maxi Wass, Friederike Hitz, Judith Schaffrath, Carsten Müller-Tidow & Lutz P. Müller. (2016) Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLOS ONE 11:10, pages e0164587.
Crossref
Jacqueline C Barrientos. (2016) Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology 12:18, pages 2077-2094.
Crossref
Sarah Wall & Jennifer A. Woyach. (2016) Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. Clinics in Geriatric Medicine 32:1, pages 175-189.
Crossref
Vladimir Vladimirovich Strugov, E.A. Stadnik, Yu.V. Virts, T.O. Silina & A.Yu. Zaritskii. (2016) Role of Patient's Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia. Clinical oncohematology 9:2, pages 162-175.
Crossref
Paula Cramer, Michael Hallek & Barbara Eichhorst. (2016) State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. Oncology Research and Treatment 39:1-2, pages 25-32.
Crossref
Paula Cramer, Petra Langerbeins, Barbara Eichhorst & Michael Hallek. (2016) Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). European Journal of Haematology 96:1, pages 9-18.
Crossref
Paula Cramer, Petra Langerbeins & Michael Hallek. (2016) Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. The Cancer Journal 22:1, pages 62-66.
Crossref
Susan M. O'BrienNicole LamannaThomas J. KippsIan FlinnAndrew D. ZelenetzJan A. BurgerMichael KeatingSiddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy & Steven E. Coutre. (2015) A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood 126:25, pages 2686-2694.
Crossref
Kanti R. Rai. (2015) Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. Journal of Hematology & Oncology 8:1.
Crossref
Javier Pinilla-IbarzJosephine Emole. (2015) Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist. Cancer Control 22:4_suppl, pages 7-16.
Crossref
Bradley Heraly & Vicki A. Morrison. (2015) How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology 6:5, pages 333-340.
Crossref
Carolyn Owen, Isabelle Bence-Bruckler, Inès Chamakhi, Cynthia Toze, Wissam Assaily, Anna Christofides & Sue Robinson. (2015) A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 15:6, pages 303-313.
Crossref
Peter Hillmen, Tadeusz Robak, Ann Janssens, K Govind Babu, Janusz Kloczko, Sebastian Grosicki, Michael Doubek, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Andrew R Pettitt, Thomas Boyd, Marco Montillo, Ira V Gupta, Oliver Wright, Iestyn Dixon, Jodi L Carey, Chai-Ni Chang, Steen Lisby, Astrid McKeown & Fritz Offner. (2015) Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. The Lancet 385:9980, pages 1873-1883.
Crossref
Esther C. van den Broek, Simone Oerlemans, Marten R. Nijziel, Eduardus F. M. Posthuma, Jan Willem W. Coebergh & Lonneke V. van de Poll-Franse. (2014) Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands. Annals of Hematology 94:1, pages 45-56.
Crossref
Hyon-Zu Lee, Barry W. Miller, Virginia E. Kwitkowski, Stacey Ricci, Pedro DelValle, Haleh Saber, Joseph Grillo, Julie Bullock, Jeffry Florian, Nitin Mehrotra, Chia-Wen Ko, Lei Nie, Marjorie Shapiro, Mate Tolnay, Robert C. Kane, Edvardas Kaminskas, Robert Justice, Ann T. Farrell & Richard Pazdur. (2014) U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia. Clinical Cancer Research 20:15, pages 3902-3907.
Crossref
Sacha Satram-Hoang, Carolina Reyes, Khang Q. Hoang, Faiyaz Momin & Sandra Skettino. (2014) Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database. Annals of Hematology 93:8, pages 1335-1344.
Crossref
Tadeusz Robak, Iwona Hus, Jerzy Błoński, Krzysztof Giannopoulos, Krzysztof Jamroziak, Jacek Roliński, Piotr Smolewski & Dariusz Wołowiec. (2014) Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL. Acta Haematologica Polonica 45:3, pages 221-239.
Crossref
Robin Foà, Ilaria Del Giudice, Antonio Cuneo, Giovanni Del Poeta, Stefania Ciolli, Francesco Di Raimondo, Francesco Lauria, Emanuele Cencini, Gian Matteo Rigolin, Agostino Cortelezzi, Francesco Nobile, Vincenzo Callea, Maura Brugiatelli, Massimo Massaia, Stefano Molica, Livio Trentin, Rita Rizzi, Giorgina Specchia, Francesca Di Serio, Lorella Orsucci, Achille Ambrosetti, Marco Montillo, Pier Luigi Zinzani, Felicetto Ferrara, Fortunato Morabito, Maria Angela Mura, Silvia Soriani, Nadia Peragine, Simona Tavolaro, Silvia Bonina, Marilisa Marinelli, Maria Stefania De Propris, Irene Della Starza, Alfonso Piciocchi, Alessandra Alietti, Eva Josephine Runggaldier, Enrica Gamba, Francesca Romana Mauro, Sabina Chiaretti & Anna Guarini. (2014) Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology 89:5, pages 480-486.
Crossref
Richard R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger D. Dansey, Michael Hallek & Susan M. O'Brien. (2014) Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine 370:11, pages 997-1007.
Crossref
A.H. Meyer, A. Stroux, K. Lerch, J. Eucker, J. Eitle, K. Hohloch, M. Andrzejak, K. Possinger, B. Dörken, A. Pezzutto & C.W. Scholz. (2014) Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Annals of Oncology 25:1, pages 210-215.
Crossref
Ju-Yoon Yoon, Ganchimeg Ishdorj, Bonnie A. Graham, James B. Johnston & Spencer B. Gibson. (2013) Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells. Apoptosis 19:1, pages 191-200.
Crossref
Tait Shanafelt. (2013) Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology 2013:1, pages 158-167.
Crossref
Francesco Zaja, Michael Mian, Stefano Volpetti, Carlo Visco, Cinzia Sissa, Ilaria Nichele, Monica Castelli, Achille Ambrosetti, Simona Puglisi, Renato Fanin, Sergio Cortelazzo, Giovanni Pizzolo, Livio Trentin, Francesco Rodeghiero, Rossella Paolini, Paolo Vivaldi, Rosaria Sancetta, Miriam Isola & Gianpietro Semenzato. (2013) Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology 88:11, pages 955-960.
Crossref
José A. García Marco, Pilar Giraldo Castellano, Javier López Jiménez, Eduardo Ríos Herranz, José Luis Sastre Moral, M. José Terol Casterá & Francesc Bosch Albareda. (2013) Guía de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocítica crónica. Medicina Clínica 141:4, pages 175.e1-175.e8.
Crossref
Ohad Benjamini, Alessandra Ferrajoli & Michael J Keating. (2013) Approach to frontline therapy in elderly chronic lymphocytic leukemia patients. Aging Health 9:3, pages 331-347.
Crossref
Anne-Sophie Michallet, Bruno Cazin, Emmanuel Bouvet, Lucie Oberic, Daniel Schlaifer, Laurent Mosser, Gilles Salles, Bertrand Coiffier, Guy Laurent & Loïc Ysebaert. (2013) First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis. Journal of Geriatric Oncology 4:2, pages 141-147.
Crossref
Tadeusz Robak. (2013) Przewlekła białaczka limfocytowa u ludzi starszych. Acta Haematologica Polonica 44:2, pages 93-98.
Crossref
Ulrich Wedding & Stuart M. Lichtman. 2013. Drug Therapy for the Elderly. Drug Therapy for the Elderly 229 247 .
Stephanie A. Gregory. (2012) Managing the patient with chronic lymphocytic leukemia: initial evaluation and first-line treatment decisions. Community Oncology 9:12, pages S77-S84.
Crossref
Stefano Molica. (2012) The initial approach to patients with chronic lymphocytic leukemia diagnosed in day-to-day practice. International Journal of Hematologic Oncology 1:1, pages 47-55.
Crossref
H.C. Kluin-Nelemans, E. Hoster, O. Hermine, J. Walewski, M. Trneny, C.H. Geisler, S. Stilgenbauer, C. Thieblemont, U. Vehling-Kaiser, J.K. Doorduijn, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, P. Feugier, M. Szymczyk, M. Hallek, S. Kremers, G. Lepeu, L. Sanhes, J.M. Zijlstra, R. Bouabdallah, P.J. Lugtenburg, M. Macro, M. Pfreundschuh, V. Proch?zka, F. Di Raimondo, V. Ribrag, M. Uppenkamp, M. Andr?W. Klapper, W. Hiddemann, M. Unterhalt & M.H. Dreyling. (2012) Treatment of Older Patients with Mantle-Cell Lymphoma. New England Journal of Medicine 367:6, pages 520-531.
Crossref
Anne-Sophie Michallet, Pierre Feugier, Alain Delmer, Loic Ysebaert, Bruno Cazin, Caroline Dartigeas, Luc Fornecker, Eric Van de Neste, Florence Cymbalista, Vincent Lévy, Veronique Leblond & Xavier Troussard. (2012) Specific treatment modalities for elderly patients with chronic lymphocytic leukemia. Aging Health 8:3, pages 317-322.
Crossref
E.C. van den Broek, A.P. Kater, S.A.M. van de Schans, H.E. Karim-Kos, M.L.G. Janssen-Heijnen, W.G. Peters, P.T.G.A. Nooijen, J.W.W. Coebergh & E.F.M. Posthuma. (2012) Chronic Lymphocytic Leukaemia in the Netherlands: Trends in incidence, treatment and survival, 1989–2008. European Journal of Cancer 48:6, pages 889-895.
Crossref
Nicole Lamanna. (2012) Treatment of Older Patients with Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports 7:1, pages 21-25.
Crossref
Tamar Tadmor & Aaron Polliack. (2012) Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices. Blood Reviews 26:1, pages 15-23.
Crossref
I. García-Escobar, J. Sepúlveda, D. Castellano & H. Cortés-Funes. (2011) Therapeutic management of chronic lymphocytic leukaemia. Critical Reviews in Oncology/Hematology 80:1, pages 100-113.
Crossref
Osnat Bairey, Rosa Ruchlemer, Neomy Rahimi-Levene, Yair Herishanu, Andre Braester, Alain Berrebi, Aaron Polliack, Avraham Klepfish & Lev Shvidel. (2011) Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study. Annals of Hematology 90:10, pages 1123-1129.
Crossref
Xavier C. BadouxMichael J. KeatingSijin Wen, Bang-Ning Lee, Mariela SivinaJames Reuben, William G. WierdaSusan M. O'BrienStefan FaderlSteven M. KornblauJan A. BurgerAlessandra Ferrajoli. (2011) Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118:13, pages 3489-3498.
Crossref
Jonathan Hebb, Sarit Assouline, Caroline Rousseau, Pierre DesJardins, Stephen Caplan, Merrill J. Egorin, Lilian Amrein, Raquel Aloyz & Lawrence Panasci. (2010) A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology 68:3, pages 643-651.
Crossref
Michael Fiegl, Florian Falkner, Michael Steurer, Niklas Zojer, Georg Hopfinger, Ferdinand Haslbauer, Guntram Winder, Daniela Voskova, Johannes Andel, Alois Lang, Yvona Brychtova, Jiri Mayer, Richard Greil & Günther Gastl. (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Annals of Hematology 90:9, pages 1083-1091.
Crossref
Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian & William G. Wierda. (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:11, pages 3016-3024.
Crossref
Paula Cramer & Michael Hallek. (2010) Prognostic factors in chronic lymphocytic leukemia—what do we need to know?. Nature Reviews Clinical Oncology 8:1, pages 38-47.
Crossref
Irina Idler, Nupur Bhattacharya, Hartmut D?hner, Stephan Stilgenbauer & Daniel Mertens. (2011) Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews 37, pages S2-S7.
Crossref
Wei‐Gang Tong & Alessandra Ferrajoli. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy 327 337 .
Kaushik Bhattacharya, Suman K. Samanta, Rakshamani Tripathi, Asish Mallick, Sarmila Chandra, Bikas C. Pal, Chandrima Shaha & Chitra Mandal. (2010) Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways. Biochemical Pharmacology 79:3, pages 361-372.
Crossref
Lukáš Smolej. (2010) How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia. Acta Medica (Hradec Kralove, Czech Republic) 53:4, pages 213-220.
Crossref
Tadeusz Robak, Krzysztof Jamroziak & Pawel Robak. (2009) Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. Drugs 69:17, pages 2415-2449.
Crossref
Michael Steurer & S. Schmidt. (2009) Chronic lymphocytic leukaemia: an update. memo - Magazine of European Medical Oncology 2:3, pages 142-145.
Crossref
Pau AbrisquetaArturo PereiraCiril Rozman, Marta Aymerich, Eva GinéCarol MorenoAna MuntañolaMaría Rozman, Neus Villamor, Kate HodgsonElías Campo, Francesc BoschEmili Montserrat. (2009) Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clínic of Barcelona experience. Blood 114:10, pages 2044-2050.
Crossref
Julio Delgado, Javier Briones & Jorge Sierra. (2009) Emerging therapies for patients with advanced chronic lymphocytic leukaemia. Blood Reviews 23:5, pages 217-224.
Crossref
Tadeusz Robak. (2009) Ofatumumab for the treatment of chronic lymphocytic leukemia. Therapy 6:4, pages 577-587.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.